Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features

Horie, Satoshi; Maeta, Hiroyuki; Endo, Kenji; Ueta, Tsuyoshi; Takashima, Kazuaki; Terada, Tadashi

doi:10.1046/j.1440-1827.2001.01159.x

Cited by 31 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous scoring systems for predicting prognosis, including Tumor-Node-Metastases (TNM) and Metastases-Age-Completeness of resection-Invasion-Size of tumor (MACIS) have been used to more accurately establish prognosis in PTC patients (3,7). Furthermore, numerous previous studies have investigated potential molecular and cytological markers of biological behavior (3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, numerous previous studies have investigated potential molecular and cytological markers of biological behavior (3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

“…However, the variation in these results was suggested to be the result of a lack of prospective studies that may reduce the selection bias, small study population sizes, the absence of multivariate analysis and the heterogeneous histological subtypes within PTC (9). Mutations in the tumor suppressor gene p53 were reported to occur in ~50% of cancers; these mutations account for the most prevalent type of genetic alteration in cancer cells (3)(4)(5)(6)(7)(8). Numerous previous studies have demonstrated that genetic mutations of p53 often occur in undifferentiated thyroid cancers.…”

Section: Introductionmentioning

confidence: 99%

“…Numerous previous studies have demonstrated that genetic mutations of p53 often occur in undifferentiated thyroid cancers. The occurrence of p53 mutations in well differentiated thyroid carcinomas, such as PTC, has not been conclusively established; but the incidence of p53 mutations has been reported as ranging between 0 and 25% (7,21). p53 protein overexpression, as determine by immunohistochemistry, was reported to be correlated with the presence of p53 gene mutations (7); however, the immunohistochemical detection of p53 overexpression has been identified in differentiated follicular and papillary thyroid carcinomas regardless of the occurrence of p53 gene mutations.…”

Section: Introductionmentioning

confidence: 99%

“…p53 protein overexpression was reported to have an incidence rate of between 11 and 59% (6,22,23). Certain studies regarding the immunohistochemical analysis of p53 protein expression have demonstrated that p53 overexpression may be used as an independent prognostic indicator for differentiated thyroid carcinomas (3)(4)(5)(6)(7)22,24).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

et al. 2015

View full text Add to dashboard Cite

Abstract. The BRAF (V600E) mutation is the most prevalent type of genetic alteration that has been identified in papillary thyroid carcinoma (PTC); in addition, previous immunohistochemical studies have revealed the overexpression of p53 protein in PTC. The aim of the present study was to investigate the prevalence of the BRAF (V600E) mutation and the expression of p53 in PTC, as well as to determine any associations between these two factors and the clinicopathological features of PTC. The study was performed on 66 PTC patients who underwent surgical tumor resection between January and December 2012. Polymerase chain reaction-based DNA amplification was used to analyze extracted DNA from the tumor specimens in order to determine the prevalence of the BRAF (V600E) mutation. In addition, immunohistochemical analysis was employed in order to evaluate the protein expression of p53 in sections of tumor tissue. Furthermore, statistical analysis was performed in order to determine any associations among the BRAF (V600E) mutation prevalence, p53 overexpression and the clinicopathological features of PTC patients, including age, gender, tumor size, multiplicity, lymph node metastasis and extrathyroidal extension. The results revealed that the BRAF (V600E) mutation was observed in 50 (75.8%) of the 66 PTC patients and overexpression of p53 was found in 52 (78.8%) of 66 cases. No significant correlations were observed between the BRAF (V600E) mutation or p53 protein overexpression and the clinicopathological features of patients. However, the BRAF (V600E) mutation demonstrated noteworthy, but non-significant, correlations with the overexpression of p53 (P=0.0854) and extrathyroidal extension (P= 0.0661). In addition, a significant correlation was observed between lymph node metastasis and bilaterality (P=0.0280). In conclusion, the present study demonstrated that the BRAF (V600E) mutation and overexpression of p53 were not significantly correlated with clinicopathological features of PTC, although notable associations were identified between BRAF (V600E) mutation and overexpression of p53 as well as extrathyroidal extension. In addition, lymph node metastasis was significantly associated with bilaterality.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Furthermore, numerous previous studies have investigated potential molecular and cytological markers of biological behavior (3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

et al. 2015

View full text Add to dashboard Cite

show abstract

p53 expression in cytology samples may represent a marker of early‐stage cancer

Policardo

Tralongo

Arciuolo

et al. 2023

Cancer Cytopathology

View full text Add to dashboard Cite

Background TP53 gene plays a major role in the negative control of cell proliferation and in the regulation of signaling cascades. TP53 mutation may have a relevant role in the malignant transformation of thyroid cells as well as thyroid tumor progression. TP53 mutation has been detected only in few well differentiated thyroid carcinomas and is absent in benign conditions. Methods A total of 162 prospective thyroid cytology and corresponding histological samples diagnosed from atypia of indeterminate significance (AUS) to malignant, were studied via immunocytochemistry for p53. Hence, 50 benign lesions (B) were used as negative control. Molecular analysis for p53 only was performed. Results The cytology resulted in 50 B, 48 AUS, 40 follicular neoplasms (FNs), 23 suspicious for malignancy (SFM), and 1 malignant (M) case. The authors reported 102 negative and 60 positive p53 cases. The 60 positive cases included 27 cases with weak and/or focal cytoplasmic positivity (+1) and 33 with cases moderate (2+) to strong (3+) cytoplasmic and/or nuclear expression. Overall, 71 cases had histology (2 B, 11 AUS, 37 FN, 20 SFM, and 1 M) including 61.7% benign and 38.2% malignant diagnoses. Only 16 of 71 (5 FN, 10 SFM, and 1 M) were p53‐positive. Furthermore, 100% AUS and 86.5% FN cases were p53‐negative, none of which had malignant histology. All p53‐positive cases were associated with a larger nodule size, tall‐cell variant subtype, multifocality, extra thyroidal infiltration, and nodal metastases. Noninvasive follicular thyroid neoplasm with papillary like nuclear features were negative for p53. Few discrepancies in p53 intensity were observed on histology; there were no differences with the molecular testing. Conclusions p53 might be useful in discriminating thyroid follicular lesions. p53 is likely to be a useful diagnostic marker in recognizing indeterminate lesions that are well‐differentiated thyroid cancers.

show abstract